{"id":"gliclazide-mr-based-glucose-lowering","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Hypoglycemia"},{"rate":"2-5","effect":"Weight gain"},{"rate":"1-3","effect":"Gastrointestinal disturbances"},{"rate":"1-2","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL427216","moleculeType":"Small molecule","molecularWeight":"323.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gliclazide binds to and closes ATP-sensitive potassium channels on the surface of pancreatic beta cells, leading to cell depolarization and opening of voltage-gated calcium channels. This influx of calcium triggers the release of stored insulin into the bloodstream, thereby lowering blood glucose levels. The modified-release (MR) formulation provides sustained drug delivery over 24 hours, allowing once-daily dosing.","oneSentence":"Gliclazide is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:00.115Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT00145925","phase":"PHASE3","title":"Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"The George Institute","startDate":"2001-06","conditions":"Diabetes Mellitus, Type 2","enrollment":11140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gliclazide MR-based glucose lowering","genericName":"Gliclazide MR-based glucose lowering","companyName":"The George Institute","companyId":"the-george-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gliclazide is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}